Pregnancy Warnings of singulair/montelukast sodium

Asthma adversely affects up to 8% of all pregnancies. Approximately one-third of pregnant women with asthma remain stable, one-third experience an improvement, and one-third experience a worsening of their condition. Untreated asthma leads to increased risk of preterm delivery, preeclampsia, vaginal hemorrhage, and pregnancy-induced hypertension. Singulair/Montelukast sodium has the advantage of once-daily dosing and oral administration. This selective leukotriene receptor antagonist decreases the activation of the cysteinyl leukotriene receptor.

The American College of Obstetricians and Gynecologists and the American College of Allergy, Asthma and Immunology suggest singulair/montelukast as an effective adjuvant therapy in pregnant women for whom resistance to other asthma treatments, or decreased effectiveness of those treatments, has been established before pregnancy.




Doctoryouneed is committed to provide the most relevant and current information about drugs. However, because drugs interact differently in each person so doctoryouneed cannot guarantee that the information contained herein is intended to cover all possible uses, side effects, drug interactions and warnings.

This material does not endorse drugs, diagnose patients, or recommend therapy and not a substitute for any medical advice. Always consult with your doctor or pharmacist before taking any prescription drugs, vitamins, herbs, supplements and over-the-counter drugs.